Head-To-Head Analysis: TScan Therapeutics (NASDAQ:TCRX) and Korro Bio (NASDAQ:KRRO)

Korro Bio (NASDAQ:KRRO) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation and risk.

Valuation & Earnings

This table compares Korro Bio and TScan Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Korro Bio	$2.38 million	59.16	-$117.26 million	($10.00)	-0.96
TScan Therapeutics	$10.32 million	2.23	-$129.77 million	($0.91)	-0.37

Korro Bio has higher earnings, but lower revenue than TScan Therapeutics. Korro Bio is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Korro Bio has a beta of 3.09, meaning that its share price is 209% more volatile than the S&P 500. Comparatively, TScan Therapeutics has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Korro Bio and TScan Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Korro Bio	1	2	6	3	2.92
TScan Therapeutics	1	5	2	0	2.12

Korro Bio presently has a consensus target price of $16.71, indicating a potential upside of 74.65%. TScan Therapeutics has a consensus target price of $2.67, indicating a potential upside of 684.31%. Given TScan Therapeutics’ higher probable upside, analysts plainly believe TScan Therapeutics is more favorable than Korro Bio.

Profitability

This table compares Korro Bio and TScan Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Korro Bio	-1,834.48%	-114.26%	-68.57%
TScan Therapeutics	-1,655.35%	-108.72%	-54.47%

Institutional & Insider Ownership

13.2% of Korro Bio shares are held by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are held by institutional investors. 4.8% of Korro Bio shares are held by insiders. Comparatively, 6.2% of TScan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

TScan Therapeutics beats Korro Bio on 9 of the 15 factors compared between the two stocks.

About Korro Bio

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

About TScan Therapeutics

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.